HSPG2 and melanoma: Immunotherapies are commonly used for melanoma and NSCLC; in this study, by integrating somatic mutational profiles and clinical therapy information for the above two cancers, we determined that HSPG2 mutations were predictive of favorable immunogenicity and ICI efficacy.